Status:
COMPLETED
Persistence of Antibody Response to N. Meningitidis Group C in Children
Lead Sponsor:
Novartis Vaccines
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Prevention of Meningococcal Infection
Eligibility:
All Genders
7+ years
Phase:
PHASE4
Brief Summary
Persistence of Antibody Response to N. meningitidis Group C in Children
Eligibility Criteria
Inclusion
- healthy children
Exclusion
- previous ascertained or suspected disease caused by N. meningitidis
- previous significant acute or chronic infections
- any other serious disease
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
489 Patients enrolled
Trial Details
Trial ID
NCT00316654
Start Date
February 1 2005
End Date
October 1 2005
Last Update
July 25 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Olsztyn, Lubartów, Kielce, Kraków, Bydgoszcz, Poland
2
Valencia, Spain